Drug Profile
AEZS 112
Alternative Names: AEZS-112; ZEN-012Latest Information Update: 22 Mar 2016
Price :
$50
*
At a glance
- Originator AEterna Zentaris Inc
- Class Antineoplastics; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Tubulin polymerisation inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Lymphoma; Solid tumours
Most Recent Events
- 23 Sep 2009 Final safety and efficacy data from a phase I trial in Solid tumours and lymphoma released by AEterna Zentaris
- 22 Apr 2009 Interim adverse events, pharmacokinetics and efficacy data from a phase I trial in solid tumours and lymphoma presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009) ,
- 10 Jan 2007 Phase-I clinical trials in Lymphoma in USA (PO)